Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q2 2026 · 10-Q
Revenue$34.46K$34.46K−59.2% vs Q2 2025 Net Income-$3.95M-$3.95MN/M vs Q2 2025 EPS Diluted$0.00$0.00— vs Q2 2025 Gross Profit$32,625−56.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived-$251,223N/M Margins · derivedGross margin94.7%+5.2 pt vs Q2 2025
Operating margin-1263.6%−919.9 pt vs Q2 2025
Net margin-11458.0%
ended Jun 30, 2026 · filed Aug 19, 2026 · 50 d after period end